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Articles
Estimates of the global, regional, and national morbidity, 
mortality, and aetiologies of lower respiratory tract 
infections in 195 countries: a systematic analysis for the 
Global Burden of Disease Study 2015
GBD 2015 LRI Collaborators*
Summary
Background The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2015 provides an up-to-date 
analysis of the burden of lower respiratory tract infections (LRIs) in 195 countries. This study assesses cases, deaths, 
and aetiologies spanning the past 25 years and shows how the burden of LRI has changed in people of all ages.
Methods We estimated LRI mortality by age, sex, geography, and year using a modelling platform shared across most 
causes of death in the GBD 2015 study called the Cause of Death Ensemble model. We modelled LRI morbidity, 
including incidence and prevalence, using a meta-regression platform called DisMod-MR. We estimated aetiologies 
for LRI using two different counterfactual approaches, the first for viral pathogens, which incorporates the aetiology-
specific risk of LRI and the prevalence of the aetiology in LRI episodes, and the second for bacterial pathogens, which 
uses a vaccine-probe approach. We used the Socio-demographic Index, which is a summary indicator derived from 
measures of income per capita, educational attainment, and fertility, to assess trends in LRI-related mortality. The 
two leading risk factors for LRI disability-adjusted life-years (DALYs), childhood undernutrition and air pollution, 
were used in a decomposition analysis to establish the relative contribution of changes in LRI DALYs.
Findings In 2015, we estimated that LRIs caused 2·74 million deaths (95% uncertainty interval [UI] 2·50 million to 
2·86 million) and 103·0 million DALYs (95% UI 96·1 million to 109·1 million). LRIs have a disproportionate effect on 
children younger than 5 years, responsible for 704 000 deaths (95% UI 651 000–763 000) and 60.6 million DALYs 
(95ÙI 56·0–65·6). Between 2005 and 2015, the number of deaths due to LRI decreased by 36·9% (95% UI 31·6 to 42·0) 
in children younger than 5 years, and by 3·2% (95% UI –0·4 to 6·9) in all ages. Pneumococcal pneumonia caused 
55·4% of LRI deaths in all ages, totalling 1 517 388 deaths (95% UI 857 940–2 183 791). Between 2005 and 2015, 
improvements in air pollution exposure were responsible for a 4·3% reduction in LRI DALYs and improvements in 
childhood undernutrition were responsible for an 8·9% reduction.
Interpretation LRIs are the leading infectious cause of death and the fifth-leading cause of death overall; they are the 
second-leading cause of DALYs. At the global level, the burden of LRIs has decreased dramatically in the last 10 years 
in children younger than 5 years, although the burden in people older than 70 years has increased in many regions. 
LRI remains a largely preventable disease and cause of death, and continued efforts to decrease indoor and ambient 
air pollution, improve childhood nutrition, and scale up the use of the pneumococcal conjugate vaccine in children 
and adults will be essential in reducing the global burden of LRI.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Lower respiratory tract infections (LRIs) are a substantial 
public health problem and a leading cause of illness and 
death in people of all ages. Previous estimates found that 
in 2013, LRIs caused more than 2·6 million deaths 
worldwide, making them the fifth leading cause of death 
overall and the leading infectious cause of death in 
children younger than 5 years.1 The burden of LRIs is 
highest in areas of low sociodemographic status, 
populations that depend on solid fuels for cooking and 
heating, and in malnourished and immunoimpaired 
populations.2 Global efforts to reduce the burden of LRIs 
using different preventive and treatment strategies 
require timely information about the burden of LRIs, 
their risk factors, and associated pathogens.
Estimates of the burden of LRIs and their aetiologies 
are being produced annually as part of the Global Burden 
of Diseases, Injuries, and Risk Factors (GBD) Study, 
which provides a unique source for tracking trends in 
LRI-related morbidity and mortality. Results from the 
GBD study that quantify the burden of LRI will help to 
measure progress towards the Sustainable Development 
Goals, including Goal 3, which is to ensure healthy lives 
and wellbeing for people of all ages.3
Lancet Infect Dis 2017; 
17: 1133–61
Published Online 
August 23, 2017 
http://dx.doi.org/10.1016/
S1473-3099(17)30396-1
See Comment page 1100
*Collaborators listed at the end 
of the Article
Correspondence to: 
Dr Ali H Mokdad, Institute for 
Health Metrics and Evaluation, 
University of Washington, 
Seattle, WA 98121, USA 
mokdaa@uw.edu
Articles
1134 www.thelancet.com/infection   Vol 17   November 2017
Here, we present results from the GBD study 2015, 
describing the burden of LRIs and four aetiologies 
(Haemophilus influenzae type B [Hib], Streptococcus 
pneumoniae [pneumococcal pneumonia], influenza, 
and respiratory syncytial virus [RSV]), covering deaths, 
episodes, disability-adjusted life-years (DALYs), risk 
factors contributing to the burden of LRIs, and the 
relationship between LRIs and social development for 
195 countries from 1990 to 2015 for both sexes and 
by age.
Methods
Modelling overview
Details on the methods for GBD 2015 are available 
elsewhere.4,5 Here, we give a brief description of the 
methods and estimation strategy for LRIs, defined as 
acute-onset physician-diagnosed pneumonia or 
bronchiolitis. We measure LRI burden using three 
metrics: deaths, episodes, and DALYs. DALYs are the 
sum of years of life lost (YLLs) because of premature 
death and years lived with disability (YLDs). We 
estimated mortality and morbidity separately. 
Flowcharts and a detailed description for each step of 
the estimation process are provided in the 
appendix pp 2–3. Input data, including information on 
sources used, and code for each step of the estimation 
process are available on the Global Health Data 
Exchange. All estimates are produced by year and by 
age, for both sexes, and for all 195 countries. Each step 
of the GBD 2015 LRI estimation process, including data 
sources, is documented in accordance with the 
Guidelines for Accurate and Transparent Health 
Estimates Reporting.6
We saved 1000 draws from a posterior distribution of 
each parameter, and we repeated each analysis 1000 times 
using these draws to retain uncertainty of every step and 
input parameters. The results are given as mean values 
with 95% uncertainty intervals (UIs) showing the 2·5 
and 97·5 percentiles of the distribution.
Mortality
The GBD Cause of Death database contains all available 
data from vital registration systems, surveillance systems, 
and verbal autopsies (summary in appendix p 4). 
We processed raw data to reconcile disparate coding 
schemes (such as the International Classification of 
Diseases 9 and 10), to redistribute poorly coded causes 
of death, and separate data by age and sex from tabulated 
cause lists.7
We estimated LRI mortality in the Cause of Death 
Ensemble model (CODEm) framework.5,8 CODEm is a 
spatiotemporal modelling platform that produces a wide 
range of submodels from cause of death data and space–
time covariates. Covariates were selected independently 
for each submodel using an algorithm that captures the 
relationships between the covariates and LRI mortality 
and provides a variety of plausible models (for full list 
of covariates, see appendix p 5). We assessed our LRI 
cause of death models using in-sample and out-of-sample 
predictive performance.
The sum of all cause-specific mortality models must be 
equal to the all-cause mortality estimate.5 We corrected 
LRI mortality estimates and estimates for other causes of 
mortality by rescaling them according to the uncertainty 
around the cause-specific mortality rate. This process is 
called CoDCorrect and ensures internal consistency 
See Online for appendix
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org/gbd-2015
Research in context
Evidence before this study
Lower respiratory tract infections are a leading cause of morbidity 
and mortality, particularly in children younger than 5 years, and 
the global burden has been estimated by several groups, 
including the Global Burden of Disease study (GBD). We build on 
previous GBD studies with updated data and methods. Updated 
cause-of-death data came from additional years of vital 
registration systems (2012–14; data from Jan 1, 1980, to Dec 31, 
2015) and by searching PubMed and Google Scholar for “verbal 
autopsy” on March 3, 2015. Updated non-fatal and aetiology 
data came from a PubMed search on June 1, 2015, for “lower 
respiratory infections”, “bronchiolitis”, and “pneumonia”. Articles 
published between Jan 1, 2012, and Dec 31, 2015, were selected 
without language restrictions.
Added value of this study
This manuscript provides a comprehensive assessment of LRI 
burden based on GBD 2015, including newer and more robust 
evidence on the mortality, morbidity, and risk factors 
associated with LRIs, including four aetiologies, and is the first 
cause-specific description of LRI in a GBD study. In addition to 
descriptions of trends in morbidity and mortality, we use the 
Socio-demographic Index to relate changes in LRI burden to 
demographic transitions and assess the effect of changing 
population characteristics and risk factor exposure to 
decompose the trends in LRI burden.
Implications of all the available evidence
We show a decreasing burden of LRI in children younger than 
5 years, but an increase in the burden in adults. Furthermore, 
we show the change in risk factor exposure globally, providing 
health professionals with valuable information needed to 
design and implement effective programmes and policies to 
reduce the burden of LRI. We also identify high-burden LRI 
regions that need more attention. Expanded use of the 
pneumococcal conjugate vaccine, interventions to improve 
under-5 nutrition, and a focus on appropriate case 
management could reduce the burden of LRI. Comprehensive 
and reliable data on LRI morbidity and mortality globally are 
still needed.
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between causes of death and respects the all-cause 
mortality envelope.5
Morbidity
LRIs were defined as clinician-confirmed or radiologically 
confirmed pneumonia or bronchiolitis and were divided 
into moderate and severe or very severe episodes on the 
basis of WHO case definitions for pneumonia.9 Input 
data were derived from a systematic literature review of 
cross-sectional and cohort studies, hospital inpatient and 
outpatient data, health-care utilisation data (USA only), 
population-representative surveys, and excess mortality 
from the GBD 2015 cause of death estimates for LRI 
(appendix pp 6–7).
LRI morbidity (incidence, prevalence, and remission) 
was modelled using DisMod-MR version 2.1 (DisMod), a 
Bayesian, hierarchical, mixed-effects meta-regression 
platform.4,10,11 DisMod adjusts for variations in study 
methods between data sources and enforces consistency 
between data for the different parameters such as 
incidence and prevalence. Incidence, prevalence, 
remission, and excess mortality were related in a 
compartmental model of disease progression. 
Epidemiological data on LRI burden were analysed 
through a geographical cascade from a global level, at 
which fixed effects for covariates are established, to the 
most detailed geographic estimation level, which was 
either the national or subnational level. Model estimates 
from higher levels of the cascade were used as priors in 
analyses of lower levels. Random effects exist for each 
geographic estimation level. Geospatial priors, space–
time covariates, random effects, and input data predicted 
incidence and prevalence of LRI episodes. Input data 
were adjusted in DisMod during the modelling process 
to meet our standard case definition using study-level 
binary covariates. These covariates described the source 
of the data and accounted for hospital-based, inpatient, 
and self-reported sources (appendix p 8).
DALYs are the sum of YLLs and YLDs and represent 
the cumulative burden of disease due to LRI.12 To 
estimate the YLDs from LRIs, we used a disability 
weight for each severity level (moderate and severe or 
very severe) and the proportion of cases that fall into 
each severity level (appendix p 7).
Aetiologies
We estimated LRI aetiologies separately from overall 
LRI mortality and morbidity using two distinct 
counterfactual modelling strategies to calculate 
population attributable fractions (PAFs) for influenza, 
RSV, Hib, and pneumococcal pneumonia. The PAF is 
the proportional reduction in LRI morbidity or mortality 
that would be observed if the exposure to the pathogen 
were zero. We did not attribute aetiologies to neonatal 
pneumonia cases or deaths because of an absence of 
reliable data in this age group, and we did not consider 
Hib in age groups older than 5 years for the same reason.
We used a vaccine probe design to estimate the PAF for 
pneumococcal pneumonia and Hib by first calculating 
the ratio of vaccine effectiveness against non-specific 
pneumonia to pathogen-specific pneumonia at the study 
level.13–15 We then adjusted this estimate by vaccine 
coverage and vaccine effectiveness to estimate country-
specific and year-specific PAF values.16,17 We did not 
account for herd immunity in our estimates. Equations 
and more about these calculations are provided in the 
appendix (pp 9–10).
For Hib, we assumed that the vaccine efficacy against 
invasive Hib disease is the same as against Hib 
pneumonia. However, we did not make the same 
assumption for pneumococcal pneumonia because a 
study of pneumococcal conjugate vaccine (PCV) found 
that the vaccine efficacy against invasive pneumococcal 
disease might be significantly higher than against 
pneumococcal pneumonia.18 We used a ratio of efficacy 
against pneumococcal pneumonia to invasive 
pneumococcal disease from this study to adjust estimates 
of vaccine efficacy against invasive pneumococcal disease 
from the other studies. We used separate pneumococcal 
pneumonia and Hib age distributions, modelled in 
DisMod, to establish the PAF by age. Finally, geography 
and year PAFs were estimated using vaccine coverage 
modelled estimates.
Influenza and RSV were estimated by calculating an 
attributable fraction that relates the odds ratio (OR) of 
LRI given pathogen detection19 and proportion of LRI 
episodes that test positive for influenza or RSV.20
We conducted a systematic literature review of the 
proportion of LRI cases that test positive for influenza 
and RSV and used the meta-regression tool DisMod to 
estimate the proportion of people with LRI who are 
positive for influenza and RSV, separately, by location, 
year, age, and sex.
Different PAFs were measured for non-fatal and fatal 
LRI episodes. Fatal PAFs were adjusted using a scalar 
from the DisMod proportion models that represents 
the relative frequency of detection in inpatient versus 
non-inpatient sample populations. In the absence of 
aetiological data from fatal cases of LRI after death, we 
assumed that episodes of LRI requiring hospital 
admission were a reasonable proxy of severe and fatal 
episodes. Mortality is lower in patients with viral 
pneumonia than in those with pneumonia with 
bacterial causes. Therefore, we adjusted the fatal PAF 
estimates by establishing the ratio of case fatality in 
viral to bacterial causes of pneumonia from hospital 
data coded specifically to these causes, representing 
the relative fatality in people who were treated 
(appendix p 13).
PAF = Proportion * (1 –          )  1
OR
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Changes in burden with development
On the basis of methods used to construct the Human 
Development Index, GBD 2015 used the Socio-
demographic Index (SDI), a summary measure of a 
country’s development based on lag-distributed income 
per capita, average educational attainment, and total 
fertility rate.5,21 We used the SDI to show how changes in 
under-5 LRI mortality and incidence are related to changes 
in development. We fitted a least-squares regression using 
a cubic spline of the relationship of SDI to LRI mortality 
and incidence for each year at the most detailed geographic 
locations.
Risk factor decomposition
Methods for risk factor attribution to LRI are described in 
detail elsewhere.22,23 Briefly, risk factors followed a PAF 
counterfactual approach in which the prevalence of 
exposure was modelled from scientific literature and 
population-representative surveys, and the relative risk of 
LRI given a risk exposure was from published meta-
analyses. We used the two leading risk groups for LRI 
DALYs from GBD 2015:22 air pollution (composed of 
household air pollution and ambient particulate matter24,25) 
and childhood undernutrition (composed of underweight, 
wasted, and stunted26), in a decomposition analysis of the 
change in LRI DALYs from 2005 to 2015. This period was 
chosen to show recent changes. The decomposition had 
four factors that contribute interdependently to LRI 
burden: undernutrition exposure, air pollution, population 
growth, and population ageing. The remaining changes 
were considered part of the unexplained causes of LRIs. A 
combinatorial process established the relative contribution 
of each of these four factors to the change in LRI DALYs.22,27
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
At the global level, under-5 LRI mortality occurred in 
104·8 children per 100 000 (95% UI 97·0–113·6) and 
varied by region and country (table 1, figure 1A). 
According to our estimates, the highest under-5 LRI 
mortalities were in sub-Saharan Africa, in Somalia 
(546·8 deaths per 100 000, 95% UI 404·5–716·4) and 
Chad (511·3 deaths per 100 000, 361·9–693·1; table 1), 
and the lowest were in Finland in western Europe (0·65 
deaths per 100 000, 0·43–0·88; figure 1A). The greatest 
overall number of under-5 LRI deaths occurred in India 
(140 649 deaths, 95% UI 122 930–160 758) because of its 
large population (table 1). The under-5 LRI mortality was 
nearly the same in males and females at the global level, 
but in south Asia, it was 1·2-times higher in girls than in 
boys (1·22 times in India and 1·24 times in Pakistan).
We calculated that, in 2015, LRIs caused 103·0 million 
DALYs (95% UI 96·1 million to 109·1 million) in all ages 
and 60·6 million DALYs (95% UI 56·0 million to 
65·6 million) in children younger than 5 years (59% of 
LRI DALYs in all ages; table 1). We estimated that in 2015, 
291·8 million episodes of LRI occurred (95% UI 
276·3 million to 307·0 million), of which 101·8 million 
episodes were in children aged younger than 5 years 
(95% UI 90·0 million to 114·4 million; table 1).
Although nearly 60% of LRI DALYs were from children 
younger than 5 years, our findings suggest that LRI 
mortality was substantial across all ages, and in elderly 
people in particular. In adults aged 70 years or older, 
1·27 million deaths (95% UI 1·15–1·34 million) were 
estimated to be caused by LRIs in 2015. In some countries, 
we estimated a much larger number of deaths due to 
LRIs in older adults (≥70 years) than in children younger 
than 5 years—eg, in China (172·3 per 100 000 [95% UI 
150·3–196·4] in older adults vs 29·2 per 100 000 
[25·7–34·7] in children aged <5 years), the USA (235·2 
per 100 000 [224·0–247·0] vs 2·7 per 100 000 [2·4–3·0]), 
and Japan (613·7 per 100 000 [588·4–639·2] vs 2·8 
per 100 000 [2·4–3·2]).
The estimated global burden of LRIs decreased greatly 
between 2005 and 2015, particularly in children younger 
than 5 years (table 1, figure 1, 2). During this period, the 
global number of under-5 deaths due to LRI decreased by 
36·9% (95% UI 31·6 to 42·0) from 1·11 million (95% UI 
1·03 million to 1·20 million) to 703 918 (651 385 to 763 039), 
with variation by region and SDI (table 1, figure 1C). 
However, the total number of LRI deaths decreased by 
3·2% (95% UI –0·45 to 6·9; table 1, figure 1D) from 
2·83 million (95% UI 2·63 million to 2·97 million) to 
2·74 million (2·50 million to 2·86 million) because of a 
slower decrease in the LRI mortality rate in all ages 
(14·3% decrease) and population growth and ageing. The 
LRI mortality rate in all ages increased in many 
geographies, notably in high-SDI countries, where it 
increased 9·6% between 2005 and 2015, from 36·2 
per 100 000 (95% UI 35·4–37·1) to 39·7 per 100 000 
(37·9–41·0). 
Between 2005 and 2015, the fastest reduction in under-5 
LRI mortality rate occurred in east and southeast Asia, 
central Europe, and tropical Latin America according to 
our estimates (>50% reduction; figure 1C). The fastest rate 
of improvement in under-5 LRI mortality occurred in 
Turkey (14% average annual decrease; figure 1C). The 
slowest decreases in under-5 mortality occurred in sub-
Saharan Africa (2·1% annual decrease), and mortality 
increased in South Sudan (0·7% annual increase; 
figure 1C). We detected a relationship between LRI 
mortality and incidence and the SDI (figure 2). The LRI 
mortality rate decreased rapidly when transitioning from 
low to middle SDI, but the mortality rate in central Asia 
was much higher than expected on the basis of 
SDI (figure 2A). The relationship between incidence and 
SDI appeared to be more linear than for mortality and 
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Figure 1: Global distribution of LRI mortality
LRI mortality rate per 100 000 people in children younger than 5 years (A) and all ages (B) in 2015. Percent change in LRI deaths per 100 000 people between 2005 and 2015 in children younger than 5 years (C) and in all 
ages (D). LRI=lower respiratory tract infection. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. 
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SDI (figure 2B). Despite reductions in LRI mortality, LRI 
incidence has decreased at a slower rate than mortality in 
children younger than 5 years (8·8%, 95% UI 6·6–11·1%) 
from 0·18 episodes per child-year (95% UI 0·16–0·20) in 
2005 to 0·15 episodes per child-year (95% UI 0·13–0·17) in 
2015, and in all ages (5·5%, 4·4–6·6) from 0·042 (95% UI 
0·039–0·044) in 2005 to 0·040 (0·037–0·042) in 2015.
LRIs were attributed to four aetiologies in GBD 2015.5 
We estimated that the bacterial causes of LRIs, 
pneumococcal pneumonia and Hib, together accounted 
for 64·1% of LRI deaths in children younger than 5 years 
(table 2). Pneumococcal pneumonia was the most 
common aetiology, leading to an estimated 392 965 deaths 
(95% UI 228 367–532 281) or 55·8% (95% UI 32·5–75·0) 
of LRI deaths in children younger than 5 years, and 
1 517 388 deaths (857 940–2 183 791), or 55·4% (31·5–79·1) 
of LRI deaths in all ages. Syria had the largest percentage 
of under-5 LRI deaths due to pneumococcal pneumonia 
(70·6%, 95% UI 43·4–91·8). Pneumococcal pneumonia 
was also responsible for a substantial number of deaths in 
the elderly population worldwide: we estimated that in 
2015, pneumococcal pneumonia killed 693 041 people 
aged 70 years and older (95% UI 295 084–1 116 257). The 
pneumococcal pneumonia PAF in children younger than 
5 years was unchanged globally between 2005 and 2015, 
but decreased in high-SDI regions (figure 3). During the 
same period, the attributable fraction of LRI deaths in 
children younger than 5 years due to Hib decreased by 
38·6% (95% UI 34·5 to 43·3), from 13·4% (–0·8 to 24·7) 
in 2005 to 8·3% (–0·5 to 15·9) in 2015 (figure 3). Hib was 
a major cause of under-5 LRI mortality in India where we 
estimated that it was responsible for 14·9% (–0·9 to 27·4) 
of LRI deaths (table 2). Hib was not attributed to any LRI 
deaths in people older than 5 years.
We estimated that RSV was responsible for 
36 363 deaths (20 355–61 545), and influenza was 
responsible for 10 151 (5 731–16 790) in children younger 
than 5 years, together accounting for 6·6% of LRI deaths 
in this age group (table 2). The burdens of RSV were 
highest in central and eastern Europe and in central 
Asia, where it accounted for more than 10% of under-5 
LRI mortality in 2015 in each of these regions (figure 3); 
the highest RSV burden was 12·3% (95% UI 6·6–21·7%) 
in Macedonia. Influenza was not frequently associated 
with under-5 LRI mortality but was responsible for more 
than 7% of deaths in all ages in central and eastern 
Europe and central Asia. The highest attributable fraction 
due to influenza was in central Asia and central and 
eastern Europe. The viral aetiologies, RSV and influenza, 
were more often associated with non-fatal episodes of 
LRI, largely because of the adjustment for the lower case 
fatality ratio in viral causes of LRI than bacterial 
aetiologies. In all ages, 15·4% (95% UI 13·0–18·4%) of 
incidence was attributable to RSV and 10·4% (8·7–11·9%) 
to influenza. Between 2005 and 2015, the influenza PAF 
increased globally in all ages (5·6% increase, 95% UI 
0·0–11·0%), and by more than 15% in North Africa, the 
Middle East, and south Asia.
We estimated that the leading risk factors for LRI 
DALYs in 2015 were childhood wasting (responsible for 
44·6% [95% UI 31·7–52·8] of DALYs worldwide), 
household air pollution (35·8%, 24·8–45·5), and 
ambient particulate matter (27·5%, 20·8–34·7). 
Suboptimal breastfeeding was the third-leading risk 
factor for under-5 DALYs globally and the leading risk 
factor for under-5 DALYs in high SDI locations. Other 
risk factors for LRI, such as smoking, alcohol use, and 
zinc deficiency, were responsible for less than 10% of LRI 
DALYs globally.
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Figure 2: LRI burden by Global Burden of Diseases Study region plotted against SDI
Under-5 LRI mortality rate per 100 000 (A) and incidence per child-year (B) is shown. Data points show 5-year 
increments from 1990 to 2015. The black line is a least-squares cubic spline regression, with knots at 0·4, 0·6, and 
0·8, using the under-5 LRI mortality rate or incidence for each geographic location, and represents the expected 
rate based on SDI alone (estimates above the black line are higher than expected and those below are lower than 
expected). More information on the formulation and theory of the SDI can be found in the Cause of Death 
GBD 2015 capstone paper.5 LRI=lower respiratory tract infection. SDI=Sociodemographic Index.
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A decomposition of the change in attributable DALYs 
between 2005 and 2015 by country is shown in figure 4, 
which includes the two leading risk factors for LRI DALYs, 
childhood undernutrition and air pollution (indoor and 
ambient). At the global level, we estimated that LRI DALYs 
have decreased 8·9% because of reduced prevalence of 
childhood undernutrition and decreased 4·3% because of 
improvements in air pollution exposure. We estimated 
that LRIs attributable to childhood undernutrition have 
decreased in many countries in sub-Saharan Africa 
during this period, particularly in Kenya (37·2% decrease), 
but the number of DALYs in Kenya have only marginally 
decreased overall, mainly because of population growth 
(figure 4E). LRI DALYs in many countries in Latin America 
and the Caribbean have decreased substantially because 
of reductions in exposure to air pollution, including a 
53% reduction attributable to these improvements in air 
pollution in Paraguay. Population ageing has contributed 
to a larger burden of LRI DALYs, particularly in high-
income countries. In adults aged 70 years and older, 
DALYs due to LRI have increased by an estimated 18·9% 
between 2005 and 2015 (data not shown). The increase in 
LRI DALYs in this age group was highest in low-SDI 
regions where the number of DALYs increased by 25·0%. 
All LRI models and results for GBD 2015 can be explored 
further online using the Institute for Health Metrics and 
Evaluation visualisations.
Discussion
The GBD 2015 study estimated that LRIs were the fifth-
leading cause of death (of 249 causes) and the leading 
infectious cause, responsible for 2·74 million deaths 
(95% UI 2·50 million to 2·86 million). LRIs were the 
third-leading cause of under-5 mortality behind preterm 
birth and neonatal encephalopathy, accounting for 12·1% 
of deaths in this age group. Our analysis suggests that 
the number of deaths due to LRI in children younger 
than 5 years decreased by 37% between 2005 and 2015. 
We found that, although all-age LRI mortality rate 
decreased, growing and ageing populations have 
contributed to no significant decline in total LRI deaths 
between 2005 and 2015. Despite dramatic improvement 
in the under-5 LRI mortality rate, LRI remains a 
preventable cause of death in young children and elderly 
adults, particularly in south Asia and sub-Saharan Africa, 
and was the second-leading cause of DALYs in 2015. The 
findings call for renewed efforts to control and prevent 
LRIs across all age groups.
Some solutions to prevent LRI deaths do not require 
major advances in technology. Measures to protect, prevent, 
and treat LRIs are highlighted in the Global Action Plan for 
Pneumonia and Diarrhoea.28 The findings from this study 
indicate that LRI incidence has declined far more slowly 
than mortality, suggesting that interventions and 
treatments that prevent mortality for LRI, particularly in 
Pneumococcal pneumonia Haemophilus influenzae type b Respiratory syncytial virus Influenza LRI deaths 
unattributed, %
Number PAF, % Number PAF, % Number PAF, % Number PAF, %
Global 392 964·8 
(228 367·0 to 532 281·4)
55·8 
(32·5 to 75·0)
58 735·8 
(–3130·9 to 114 528·3)
8·3 
(–0·5 to 15·9)
36 362·5 
(20 355·4 to 61 544·9)
5·2 
(2·9 to 8·6)
10 150·6 
(5 731·1 to 16 789·6)
1·4 
(0·8 to 2·4)
29·3 
(–1·9 to 63·8)
India 82 448·4 
(51 126·5 to 112 117·5)
58·7 
(36·6 to 75·8)
20 987·1 
(–1164·2 to 39 659·8)
14·9 
(–0·9 to 27·4)
8414·9 
(4689·0 to 14 116·9)
6·0 
(3·4 to 10·1)
2351·7 
(1326·4 to 3790·8)
1·7 
(1 to 2·7)
18·7 
(–16·0 to 59·9)
Nigeria 33 810·9 
(17 837·6 to 53 327·8)
56·5 
(33·9 to 75·3)
5249·7 
(–239·1 to 11 278·1)
8·8 
(–0·5 to 17·4)
2297·1 
(1040·9 to 4276·5)
3·8 
(2 to 6·6)
396·4 
(188·9 to 745·6)
0·7 
(0·4 to 1·1)
30·2 
(–0·4 to 64·2)
Pakistan 20 025·0 
(9714·1 to 32 523·3)
50·0 
(26·5 to 75·9)
2565·7 
(–106·3 to 5580·4)
6·5 
(–0·3 to 13·4)
3263·4 
(1664·4 to 5706·6)
8·3 
(4·6 to 14·3)
556·5 
(269·5 to 1057·0)
1·4 
(0·8 to 2·5)
32·8 
(–6·1 to 68·4)
Democratic 
Republic of 
the Congo
21 483·2 
(9964·1 to 35 809·1)
55·8 
(29 to 80·9)
2966·7 
(–147·6 to 6748·8)
7·7 
(–0·4 to 15·6)
1612·8 
(739·2 to 3251·3)
4·2 
(2·3 to 7·4)
677·7 
(308·1 to 1309·8)
1·8 
(0·9 to 3)
30·5 
(–6·9 to 68·2)
Ethiopia 14 148·3 
(6769·4 to 22 672·6)
54·2 
(30·5 to 76·1)
2121·4 
(–100·8 to 4583·1)
8·1 
(–0·4 to 16·4)
606·2 
(255·1 to 1219·1)
2·3 
(1·1 to 4·4)
298·2 
(115·4 to 620·2)
1·1 
(0·5 to 2·2)
34·3 
(0·9 to 68·3)
China 12 177·0 
(7171·5 to 16 901·6)
50·2 
(30 to 66·7)
857·9 
(–42·1 to 1825·4)
3·5 
(–0·2 to 7·3)
896·8 
(494·2 to 1548·5)
3·7 
(2·1 to 6·3)
303·4 
(167·8 to 519·5)
1·3 
(0·7 to 2·1)
41·3 
(17·6 to 67·4)
Bangladesh 8460·8 
(4028·1 to 13 627·8)
39·8 
(20·4 to 59·8)
733·2 
(–32·6 to 1645·8)
3·4 
(–0·2 to 7·4)
1258·0 
(665·0 to 2238·3)
5·9 
(3·2 to 10·5)
154·2 
(78·5 to 269·6)
0·7 
(0·4 to 1·3)
50·2 
(21·0 to 76·2)
Afghanistan 11 920·0 
(5681·6 to 19 034·2)
62·2 
(36·7 to 84·1)
1848·8 
(–93·1 to 4006·6)
9·7 
(–0·5 to 18·9)
1702·4 
(713·2 to 3350·3)
8·9 
(4·2 to 16·6)
318·0 
(134·4 to 646·0)
1·7 
(0·8 to 3·2)
17·5 
(–22·8 to 58·8)
Tanzania 9203·7 
(4418·1 to 14 959·4)
51·9 
(27·3 to 74·1)
801·1 
(–31·0 to 1898·7)
4·5 
(–0·2 to 9·6)
450·9 
(197·7 to 876·2)
2·5 
(1·2 to 4·8)
162·6 
(77·9 to 304·9)
0·9 
(0·5 to 1·6)
40·2 
(9·9 to 71·2)
Indonesia 9573·2 
(4522·3 to 14 806·7)
62·5 
(38·6 to 82·2)
1298·4 
(–73·5 to 2818·6)
8·5 
(–0·5 to 16·7)
567·3 
(246·7 to 1086·3)
3·7 
(1·9 to 6·6)
360·0 
(160·4 to 654·2)
2·4 
(1·3 to 4)
22·9 
(–9·5 to 58·7)
Data are n or % (95% uncertainty interval). The number of deaths in children younger than 5 years are shown for each aetiology at the global level and for each of the ten countries with the highest LRI mortality 
burden. Aetiological attributable fractions are based on a counterfactual modelling strategy and do not necessarily sum to 100% in a given location. LRI=lower respiratory tract infection. PAF=population 
attributable fraction.
Table 2: Number of deaths and PAFs of LRI-related deaths in children aged 5 years or younger, by aetiology, in top ten countries with highest under-5 LRI mortality burden
For the Institute for Health 
Metrics and Evaluation 
visualisations see http://www.
healthdata.org/gbd/data-
visualizations
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children younger than 5 years, have been much more 
successful reducing the burden of LRI than prevention of 
disease incidence. According to this study, the reduction in 
LRI DALYs can be traced to Hib vaccine use, decreased 
exposure to indoor air pollution, and a reduction in 
undernutrition in children younger than 5 years.
Although such interventions were not estimated in 
GBD 2015, improved access to health care and emphasis 
on appropriate treatment have probably played a crucial 
role in reducing LRI mortality, with proper treatment 
reducing mortality by 20–42%.2,29–31 How much of the 
decrease in mortality is due to proper adherence and 
implementation of the WHO Integrated Management of 
Childhood Illness recommendations is unclear, because 
data on its uptake are scarce. These recommendations, 
which are based on symptom-based screening criteria 
such as fast breathing or lower chest wall indrawing, 
have been updated several times, and their application 
varies substantially. Divergence from these criteria might 
lead to inappropriate treatment and misuse of 
antibiotics.29,32,33 Our results suggest that most severe 
LRIs have bacterial causes, whereas pneumococcal 
pneumonia and Hib have effective Gavi-supported 
vaccines, emphasising that combined appropriate case 
management and vaccine use might prevent many 
episodes of LRI and reduce dependence on antibiotics.34
In 2015, approximately 65% of children younger than 
5 years received the Hib vaccine and 40% received the 
PCV.35 At the global level, the PAF of Hib on LRI deaths 
decreased 37·8% between 2005 and 2015, reflecting the 
expanded use and introduction of the vaccine during this 
time, particularly in countries that received support from 
Gavi.36 Despite the growing use of PCV, pneumococcal 
pneumonia mortality has not decreased significantly at 
the global level and has decreased more slowly than Hib, 
in part because the PAF for pneumococcal pneumonia 
depends on the PAF for Hib; as Hib decreases, we 
assume that pneumococcal pneumonia must increase to 
account for overall LRI aetiological attribution.
The expanded use of PCV might have several indirect 
effects on LRI burden. PCV might prevent influenza and 
RSV mortality, because up to half of severe viral infections 
are complicated by pneumococcal pneumonia.37 Further, 
PCV might induce large indirect (herd) vaccine effects 
that protect unvaccinated populations, such as adults and 
elderly people.38 Amid debate about quantifying the effect 
of indirect vaccine effectiveness for adults in populations 
with infant vaccine use,39 our findings highlight the 
burden of LRI in the elderly population, including nearly 
700 000 deaths in people aged older than 70 years due to 
pneumococcal pneumonia. Expanding access to the 
vaccine in adults might substantially reduce the burden 
of LRI.
Our results suggest that LRIs were the second-leading 
cause of DALYs globally in 2015 after ischaemic heart 
disease.4 Our results also suggest that decreases in under-5 
undernutrition have substantially reduced LRI DALYs, and 
are responsible for nearly 9% of the decline during this 
period.22,40,41 The greatest reduction in LRI DALYs due to 
childhood undernutrition between 2005 and 2015 occurred 
in east and southeast Asia. This finding is notable because 
improved childhood nutrition will have effects beyond 
reducing LRI DALYs and is also likely to reduce the burden 
of disease caused by diarrhoea and measles.40 Emphasis 
on sustainable agriculture, supplementary nutritional 
programmes, and equitable distribution of food through 
the Sustainable Development Goals will be necessary for 
continued reductions in the global burden of LRI.42
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Figure 3: Attributable fraction of LRI mortality in children younger than 
5 years in 2015
Aetiologies for each GBD region are ordered by the global ranking. Numbers show 
the population attributable fraction in 2015, and colours show the percent change 
from 2005 to 2015. LRI=lower respiratory tract infection.
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Household solid fuel use as a risk factor for LRI has 
decreased since 2005, particularly in Latin America and 
southeast Asia, which are undergoing rapid urbanisation 
and economic development. Economic development that 
shifts energy requirements away from household burning 
of biomass might reduce exposure to indoor air pollution 
at the expense of outdoor and ambient particulate matter 
from large-scale energy production facilities like coal-
burning power plants.43 Providing affordable clean energy 
options in low sociodemographic areas of the world is 
covered by the Sustainable Development Goals, but 
achieving this aim will be a challenge and the risk of LRIs 
might depend on its success.3
Our estimates of LRI mortality, morbidity, and aetiology 
attribution are limited by data availability and especially 
the sparsity of data in sub-Saharan Africa, the region with 
the greatest LRI burden and need for high-quality data 
(appendix pp 5, 7, and 14–15). Only extremely scarce verbal 
autopsy data are available for large populations and the 
data that are available in Africa and south Asia might be of 
low quality, as measured by indices such as completeness, 
detail, internal consistency, and timeliness. Better 
surveillance systems, including standard reporting 
mechanisms and case definitions, in Africa and south and 
southeast Asia would substantially reduce a major source 
of uncertainty in the LRI mortality estimates.44 Assessing a 
systematic bias in morbidity or mortality estimates is 
difficult because of data quantity and quality. The predictive 
modelling approaches used in GBD 2015 rely on covariates 
and shared information across space and time to fill in 
these areas and the data gaps are reflected in the 
uncertainty intervals in the estimates (table 1).
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Even with the application and expanded use of PCR 
diagnostic techniques, data on the aetiology of 
pneumonia remain sparse, particularly in areas with 
high disease burden. This scarcity of data is largely due 
to the difficulty of obtaining appropriate samples for 
testing, particularly in children, the relatively high cost of 
PCR, and challenges in culturing and diagnosing many 
pathogens that cause respiratory infections.45,46 Studies 
that have attempted to elucidate the aetiology of 
childhood pneumonia, frequently using nasopharyngeal 
swabs or lung aspirates, have had poor success in 
identifying an obvious aetiological agent.45,47 Atypical 
pathogens, including nosocomial infections such as 
Staphylococcus aureus, or intracellular pathogens like 
Mycoplasma pneumoniae, might be important aetiologies 
for LRIs and are not included in GBD 2015.48,49 Such 
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Figure 4: Risk factor 
decomposition of the change 
in attributable DALYs in all 
ages between 2005 and 2015
(A) Southeast Asia, east Asia, 
and Oceania; (B) north Africa 
and Middle East; (C) south 
Asia; (D) central Europe, 
eastern Europe, and central 
Asia; (E) sub-Saharan Africa; 
(F) Latin America and 
Caribbean; and 
(G) high-income WHO regions. 
Black dots show the overall 
percentage change in LRI 
DALYs and colours show 
contribution of different 
factors to the rate of change. 
Bars to the left of zero show a 
reduction in attribution and 
bars to the right show an 
increase. LRI=lower respiratory 
tract infection. 
DALY=disability-adjusted 
life-year.
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omissions might limit the ability to attribute LRI episodes 
and deaths to pathogens because our analysis is not able 
to show whether the unattributed LRI episodes and 
deaths are due to the four aetiologies included in 
GBD 2015 or other pathogens. Results from the 
Pneumonia Etiology Research for Child Health Project,50 
a seven-site case-control study in sub-Saharan Africa and 
south Asia, were not available for inclusion in GBD 2015 
but might provide evidence on LRI aetiologies such as 
additional pathogens, the relative contribution of each 
aetiology, and viral–bacterial coinfections.
The attributable fraction strategy for Hib and 
pneumococcal pneumonia assumes that the vaccine 
efficacy against invasive disease is the same as for 
pneumonia. A study by Bonten and colleagues18 using a 
urine antigen test in elderly adults suggests that the vaccine 
efficacy of PCV13 might be up to a third higher against 
invasive pneumococcal disease than against pneumococcal 
pneumonia.18 We have adjusted our estimates of vaccine 
effectiveness from other studies using this ratio but 
recognise the uncertainty around the application of a single 
study in elderly adults to all other studies and decided to 
use a flat distribution centred on the mean ratio from the 
study to reflect this uncertainty. Application of this 
diagnostic test is unsuitable for children and is complicated 
by the frequent nasopharyngeal carriage rate in children, 
perhaps up to 90% in low-income settings.45,51,52 We do not 
account for serotype replacement or changes in serotype 
prevalence due to the introduction of PCV, which might 
be an important factor in the burden of pneumococcal 
pneumonia and the effectiveness of the vaccine at the 
population level.29
Only four randomised controlled trials on Hib vaccine 
efficacy have been done in children younger than 5 years. 
Despite a plausible disease burden in older children and 
adults, we decided to apply the attributable fraction of 
LRI episodes and deaths due to Hib pneumonia to the 
under-5 age group only. The lower bound of the Hib PAF 
estimates is below zero (not statistically significant) at 
the global level, reflecting in part the scarcity of reliable 
data on Hib vaccine efficacy.
The attribution of the viral pathogens to LRI mortality 
was based on the relative case fatality of bacterial to viral 
aetiologies, and cases of LRI admitted to hospital might 
not be representative of cases not admitted to hospital. 
Efforts to improve surveillance, such as the African 
Network for Influenza Surveillance and Epidemiology,53 
are essential in tracking the burden of influenza and 
other LRI aetiologies and for appropriate and timely 
response to epidemics. We excluded data describing 
pandemic H1N1 influenza to avoid biasing global and 
temporal trends in influenza burden, but doing so might 
have led to lower estimates of influenza burden, 
particularly since 2008.
The GBD 2015 estimates of LRI mortality and burden 
are generally similar to the GBD 2013 estimates.1,10 Global 
under-5 mortality was lower in GBD 2015 than GBD 2013, 
primarily because of decreased estimates in Nigeria 
(appendix pp 18–21). Nigeria is a high-population, 
high-burden country with sparse data and estimates in 
this high-burden country are influenced by regional trends 
and covariates; limitations shared by much of sub-Saharan 
Africa. In fact, only a single datapoint informed cause of 
death models in this country. Mortality and morbidity 
were different between GBD versions in China and India 
(appendix pp 18–21), which reflects in part that these 
countries are now modelled subnationally (data not 
shown), allowing for greater accuracy and precision in 
geographic disparities. Disparities in LRI burden by 
wealth, geography, and other subpopulation 
characteristics might be missed when national-level 
estimates are presented. The GBD study will be produced 
annually starting with GBD 2016, and future iterations 
will feature finer spatial resolution, including mapping 
the burden of LRI on a 5 × 5 km level, which will enable 
tracking of the burden at a very fine resolution.
Our estimates of pneumonia mortality in children 
younger than 5 years differ from those produced by the 
WHO Department of Evidence, Information and 
Research and the Maternal and Child Epidemiology 
Estimation (MCEE) group. The GBD 2015 estimates for 
under-5 mortality due to LRI in 2015 (704 000 deaths, 
95% UI 651 000–763 000) were much lower than those 
from the MCEE (920 000 deaths).54,55 The difference in 
total under-5 deaths was greatest for Nigeria and India 
(appendix p 25). 
Despite substantial reductions in under-5 LRI mortality 
in many countries, the burden remains high, particularly 
in areas of low sociodemographic development, and has 
increased in some populations, particularly elderly 
people. Estimates of the global burden of LRI will be 
improved by more high-quality data on mortality, 
morbidity, and aetiologies, especially in sub-Saharan 
Africa where the burden is highest and data are most 
scarce. The creation and expansion of civil registration 
systems in Africa and south Asia are gaining momentum, 
and such data will not only improve global comparative 
mortality assessments such as the GBD study, but also 
increase the evidence for guiding decision about local 
policy.44,56 Improvements in diagnostics for LRI 
aetiologies, including those appropriate for children 
younger than 5 years to better understand the unique 
contribution of each aetiology to the LRI burden, will 
help guide targeted interventions such as vaccination. 
Continuing to emphasise the importance of appropriate 
case management, to expand the use of PCV, and to 
reduce childhood undernutrition and exposure to air 
pollution will accelerate the reduction in LRI disease 
burden.
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